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Dear Editor,
W
e  greatly  enjoyed  reading  the  excellent 
meta-analysis by Alavian and colleagues (1)   
on the efficacy and safety of peginterferon (PEG-
IFN) alpha-1a vs. 2b for the treatment of chronic 
hepatitis C virus (HCV) infection. 
The  immune  effects  of  interferons,  often  in 
combination with other drugs, have been utilized to 
treat several diseases, such as HCV and HCV-related 
autoimmune  diseases  and  liver  diseases.  Several 
different types of interferon are approved for use in 
humans. For instance, in January 2001 the Food and 
Drug Administration approved the use of pegylated 
interferon-alpha; in this formulation, polyethylene 
glycol is added to make the interferon last longer 
in the body. Peginterferon alpha-2b (Pegintron) was 
the  first  treatment  approved  for  public  use,  and 
approval for peginterferon alpha-2a (Pegasys), which 
has a longer duration in serum, followed in October 
2002. When used with the antiviral drug ribavirin, 
pegylated interferon is effective in the treatment of 
HCV; however, up to now, there is no convincing 
clinical  evidence  that  peginterferon  alpha-2a  has 
a  different  response  than  peginterferon  alpha-2b 
treatment.  In  the  meta-analysis  reported  herein,   
peginterferon alpha-2a showed an early virological 
response at treatment week 4 (EVR) and a sustained 
virological response (SVR) at week 12, and alpha-2a 
had a better response than did alpha-2b in patients 
with HCV genotypes 1-4 (OR 1.38) and genotype 2 
(OR 4.06). These data are of interest because single 
studies  conducted  before  2009  suggested  a  trend 
towards peginterferon alpha-2a, but the treatment 
reached significance only when several studies were 
pooled together (hereafter the meta-analysis refers 
to 3,518 grouped patients). In addition, the review 
also offers important information regarding safety, 
indicating a difference among the two treatments 
in only the causation of neutropenia (<750c/mm3), 
with an overall estimate of OR 0.75 of discontinuing 
the peginterferon alpha-2a treatment. Usually, the 
use  of  a  granulocyte  colony  stimulating  factor  is 
effective in correcting neutropenia (2, 3).
Thus, the review provides important information 
about  the  clinical  steps  and  best  practices  in 
the  treatment  of  chronic  HCV  infection  with 
peginterferon alpha-2a. A limitation of the study is 
that no data were reported on liver histology, an area 
that should be explored in the future.
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Furthermore,  despite  significant  progress  in 
HCV antiviral therapy, tolerance for and compliance 
with PEG-IFN/Ribavirin therapy remain a serious 
problem  because,  as  reported  by  the  authors,  the 
treatment may induce a sustained clearance of the 
virus  and  clinical  improvement  in  a  median  of 
75% people with HCV genotypes 2 or 3, but the 
treatment  is  effective  in  less  than  50%  of  people 
infected with genotype 1, the most common form 
of  HCV  in  both  the  United  States  and  Western 
Europe. Thus, future perspectives will be focused on 
developing new drugs; indeed, the most in advanced 
clinical  developments  are  direct  antiviral  agents. 
The  NS3  protease,  essential  for  viral  replication, 
represents an important target for these therapies. 
The clinical efficacy of NS3 protease inhibitors was 
first  demonstrated  with  compounds  targeting  the 
enzyme  active  site  BILN  2061,  boceprevir  (SCH 
503034), and telaprevir (VX-950) in monotherapy 
and  in  combination  with  PEG-IFN.  During 
boceprevir  or  telaprevir  monotherapy,  multiple 
resistance mutations were selected (4, 5). Therefore, 
combination  therapy  with  pegylated  interferon-
alfa, ribavirin, or other direct antiviral drugs seems 
mandatory to avoid the development of resistance. 
The safety and efficacy of plus peginterferon alfa-2b 
and ribavirin in the treatment of naïve patients with 
chronic  hepatitis  C  genotype  1  infection  showed 
response rates of up to 75% for boceprevir and 68% 
for Telaprevir (6, 7), but the underlying mechanism 
of the response to the treatment is still not clear. 
Thus,  although  encouraging  clinical  results  have 
been  achieved  with  these  first-generation  protease 
inhibitors,  additional  improvement  in  inhibitor 
potency  and  pharmacokinetic  properties  will  be 
pursued  to  increase  SVR.  Moreover,  predictive 
biomarkers  of  poor  virological  response  to  the 
treatments will be investigated in amino acid (aa) 
substitution  studies  of  host  genes  (8),  analyses  of 
HCV gene regions of infected patients (9, 10), and/
or the role of drugs on host immune responses such 
as upregulation of major histocompatibility complex 
molecules, increases in immunoproteosome activity, 
and  the  activation  of  certain  immune  cells  (e.g., 
macrophages and natural killer cells). In addition, 
the  evidence  up  to  this  point  has  indicated  that 
HCV can bind and internalize into primary B-cells; 
furthermore,  one  analysis  found  that  HCV  failed 
to create a productive infection in these cells, and 
the  virus  showed  in  vitro  an  enhanced  infectivity 
compared with the extracellular virus and an ability 
to promote B-cell adhesion to hepatoma cells (11). 
Thus, the role of B-cell elimination, which serves 
as long-term HCV reservoirs, should be considered 
in  the  future.  With  respect  to  this  topic,  one  of 
our recent papers (12) noted a significant depletion 
of inflammatory cells and a tricking regression of 
hepatocytolytic  foci  in  histological  liver  samples 
obtained at the end of a PEG-IFN/Ribavirin, plus 
rituximab treatment (PIRR treatment). The results of 
the study thus indicated that PIRR, including B-cell 
depletion due to the addition of a monoclonal anti-
CD20 antibody, rituximab, in anti-HCV therapy can 
establish a prolonged histological remission rather 
than an increased rate of eradication of HCV infection 
as compared with PEG-IFN/Ribavirin combination, 
at least in patients with cryoglobulinemia.
References
1.  Alavian SM, Behnava B, Tabatabaei SV. The Comparative 
Efficacy  and  Safety  of  Peginterferon  Alpha-2a  vs.  2b  for 
the Treatment of Chronic HCV Infection: A Meta-Analysis. 
Hepat Mon. 2010;10(2):121-31.
2.  Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa 
N.  Effects  of  interferon-alpha  on  peripheral  neutrophil 
counts  and  serum  granulocyte  colony-stimulating  factor 
levels in chronic hepatitis C patients. Cytokines Cell Mol 
Ther. 2000;6(3):149-54.
3.  Van Thiel DH, Faruki H, Friedlander L, et al. Combination 
treatment  of  advanced  HCV  associated  liver  disease 
with  interferon  and  G-CSF.  Hepatogastroenterology. 
1995;42(6):907-12.
4.  Kieffer  TL,  Sarrazin  C,  Miller  JS,  et  al.  Telaprevir  and 
pegylated  interferon-alpha-2a  inhibit  wild-type  and 
resistant  genotype  1  hepatitis  C  virus  replication  in 
patients. Hepatology. 2007;46(3):631-9.
5.  Susser  S,  Welsch  C,  Wang  Y,  et  al.  Characterization  of 
resistance to the protease inhibitor boceprevir in hepatitis 
C virus-infected patients. Hepatology. 2009;50(6):1709-18.
6.  Lawitz  E,  Rodriguez-Torres  M,  Muir  AJ,  et  al.  Antiviral 
effects and safety of telaprevir, peginterferon alfa-2a, and 
ribavirin  for  28  days  in  hepatitis  C  patients.  J  Hepatol. 
2008;49(2):163-9.
7.  McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir 
with peginterferon and ribavirin for chronic HCV genotype 
1 infection. N Engl J Med. 2009;360(18):1827-38.
8.  Thomas DL, Thio CL, Martin MP, et al. Genetic variation 
in IL28B and spontaneous clearance of hepatitis C virus. 
Nature. 2009;461(7265):798-801.
9.  Akuta N, Suzuki F, Hirakawa M, et al. Association of amino 
acid  substitution  pattern  in  core  protein  of  hepatitis  C 
virus genotype 2a high viral load and virological response 
to interferon-ribavirin combination therapy. Intervirology. 
2009;52(6):301-9.
10. Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values 
of amino acid sequences of the core and NS5A regions in 
antiviral therapy for hepatitis C: a Japanese multi-center 
study. J Gastroenterol. 2009;44(9):952-63.
11. Stamataki  Z,  Shannon-Lowe  C,  Shaw  J,  et  al.  Hepatitis 
C virus association with peripheral blood B lymphocytes 
potentiates viral infection of liver-derived hepatoma cells. 
Blood. 2009;113(3):585-93.
12. Dammacco  F,  Tucci  FA,  Lauletta  G,  et  al.  Pegylated 
interferon-{alpha},  ribavirin,  and  rituximab  combined 
therapy of hepatitis C virus-related mixed cryoglobulinemia: 
a long-term study. Blood. 2010. [in press].